Yale Tested 51 Antiaging Interventions. Only 13 Actually Worked.
BiohackingA Yale University-led study published in Nature Medicine on August 21, 2026 tested 51 human intervention studies — 3,128 blood samples — for genuine epigenetic aging effects. The methodology was more rigorous than most longevity research: 16 epigenetic clocks and 94 DNA methylation biomarkers measured simultaneously, with a two-bar reproducibility standard applied before calling anything an effect.
The result: 26 of 51 interventions (51%) showed no significant change in epigenetic age. After applying false-positive corrections, only 13 of the original 51 interventions produced genuine, reproducible effects. Five interventions didn’t just fail — they actually increased epigenetic age.
What “Moved Nothing” Means
The study’s standard is stricter than most longevity research you’ve read. To count as a genuine effect, an intervention had to move biomarkers in the same direction and at comparable magnitude — and then replicate that result across independent studies of the same intervention. Most single-study findings don’t survive this kind of cross-study consistency check.
The 26 failed interventions aren’t necessarily “proven useless” — some lacked adequate study power, sample diversity, or follow-up duration. But they didn’t meet the bar for “we have reliable evidence this changes your epigenetic age.”
Senolytics Failed the Test
The most notable failure: senolytics — drugs designed to clear senescent (“zombie”) cells, which accumulate with age and drive inflammatory damage. Senolytics have attracted significant longevity investment and media coverage in the past several years, with products like dasatinib + quercetin drawing substantial clinical interest.
In the Yale analysis, senolytics “didn’t line up” — different biomarkers moved in opposite directions within the same studies, failing the reproducibility standard. That’s not a finding that senolytics don’t work in any sense — the mechanism is real, and senescent cell accumulation is a genuine aging driver. It’s a finding that current senolytics haven’t demonstrated consistent, reproducible epigenetic age reversal in humans as measured by this methodology.
What Actually Worked
Two categories produced genuine effects that survived the cross-study consistency check:
Anti-TNF therapies — drugs used primarily for rheumatoid arthritis and inflammatory bowel disease (infliximab, adalimumab, and related biologics). These “shifted nearly all second-generation biomarkers by comparable amounts” across studies. The implication isn’t that everyone should take RA drugs — it’s that systemic inflammation suppression may be a more direct lever on epigenetic aging than most dedicated longevity compounds currently on the market.
Mediterranean diet protocols — decreased overlapping biomarkers consistently. Not surprising, but the consistency of the effect across independent studies under this methodology is notable. The Mediterranean diet continues to produce cleaner longevity signals across more measurement systems than almost any supplement category.
The Conflict of Interest Disclosure
Several of the study’s authors are affiliated with TruDiagnostic, a commercial epigenetic testing company that supplied datasets and algorithms analyzed in the research. This doesn’t invalidate the findings — TruDiagnostic’s epigenetic clock data is widely used in longevity research, and the Nature Medicine peer review process is rigorous — but it’s worth noting when evaluating which biomarkers were selected and how results were framed.
The So What
The practical implication isn’t nihilistic about longevity supplementation. It’s specific: the interventions with the strongest epigenetic evidence right now are anti-inflammatory (anti-TNF, Mediterranean diet), not the supplement categories that have attracted the most consumer interest (senolytics, NAD+ precursors, specific peptides). If your stack is heavy on senolytic-adjacent compounds and light on systematic inflammation management, this study suggests a rebalancing conversation worth having with your longevity-focused clinician.
The 13 interventions that did work represent a much narrower, better-evidenced target set than the field’s marketing suggests. That’s not a pessimistic reading — it’s a precision reading. Knowing what the evidence actually supports is more useful than acting on what sounds most promising.
Source: Longevity Technology
Content created with AI assistance and reviewed for accuracy.
Join the conversation
Stack Insiders is our free community for readers who want to go deeper — share resources, ask questions, and connect with others across every vertical we cover.
Join Stack Insiders →